LIST OF TABLES
TABLE 01. TOTAL COMMITTED PUBLIC FUNDING FOR ANTIBACTERIAL RESISTANCE RESEARCH BY JPIAMR COUNTRIES
TABLE 02. RECOMMENDED DOSAGE SCHEDULE FOR CEFTAZIMIDE
TABLE 03. AVERAGE SELLING PRICE ($) OF CEFTAZIMIDE
TABLE 04. RECOMMENDED DOSAGE SCHEDULE FOR CEFTIN
TABLE 05. CEFUROXIME MARKET VALUE, 2017-2025 ($MILLION)
TABLE 06. AVERAGE SELLING PRICE ($) OF CEFUROXIME
TABLE 07. NONCLASSIFIED AND COMBINATION CEPHALOSPORIN
TABLE 08. GLOBAL CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 09. FIRST-GENERATION CEPHALOSPORIN
TABLE 10. FIRST-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 11. SECOND-GENERATION CEPHALOSPORIN
TABLE 12. SECOND-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 13. THIRD-GENERATION CEPHALOSPORIN
TABLE 14. THIRD-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 15. FOURTH-GENERATION CEPHALOSPORIN
TABLE 16. FOURTH-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 17. FIFTH-GENERATION CEPHALOSPORIN
TABLE 18. FIFTH-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 19. GLOBAL CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 20. BRANDED CEPHALOSPORIN DRUGS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 21. GENERIC CEPHALOSPORIN DRUGS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 22. GLOBAL CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 23. CEPHALOSPORIN DRUGS THAT ARE GIVEN AS INJECTION
TABLE 24. CEPHALOSPORIN INJECTIONS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 25. ORAL CEPHALOSPORIN DRUGS
TABLE 26. ORAL CEPHALOSPORIN DRUGS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 27. GLOBAL CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 28. CEPHALOSPORIN DRUGS USED TO TREAT RESPIRATORY TRACT INFECTION
TABLE 29. CEPHALOSPORIN MARKET FOR RESPIRATORY TRACT INFECTION, BY REGION, 2017-2025 ($MILLION)
TABLE 30. CEPHALOSPORIN DRUGS USED TO TREAT SKIN INFECTION
TABLE 31. CEPHALOSPORIN MARKET FOR SKIN INFECTION, BY REGION, 2017-2025 ($MILLION)
TABLE 32. CEPHALOSPORIN DRUGS USED TO TREAT EAR INFECTION
TABLE 33. CEPHALOSPORIN MARKET FOR EAR INFECTION, BY REGION, 2017-2025 ($MILLION)
TABLE 34. CEPHALOSPORIN DRUGS USED TO TREAT URINARY TRACT INFECTION
TABLE 35. CEPHALOSPORIN MARKET FOR URINARY TRACT INFECTION, BY REGION, 2017-2025 ($MILLION)
TABLE 36. CEPHALOSPORIN DRUGS USED TO TREAT INFECTION CAUSED DUE TO GONORRHOEA
TABLE 37. CEPHALOSPORIN MARKET FOR SEXUALLY TRANSMITTED INFECTION, BY REGION, 2017-2025 ($MILLION)
TABLE 38. CEPHALOSPORIN DRUGS USED FOR OTHER APPLICATIONS
TABLE 39. CEPHALOSPORIN MARKET FOR OTHER APPLICATIONS, BY REGION, 2017-2025 ($MILLION)
TABLE 40. GLOBAL CEPHALOSPORIN MARKET, BY REGION ($MILLION), 2017-2025
TABLE 41. NORTH AMERICA CEPHALOSPORIN MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 42. U.S. CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 43. U.S. CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 44. U.S. CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 45. U.S. CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 46. CANADA CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 47. CANADA CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 48. CANADA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 49. CANADA CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 50. MEXICO CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 51. MEXICO CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 52. MEXICO CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 53. MEXICO CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 54. NORTH AMERICA CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 55. NORTH AMERICA CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 56. NORTH AMERICA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 57. NORTH AMERICA CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 58. TOP FIVE EUROPEAN COUNTRIES PER STI, 2000-2013
TABLE 59. EUROPE CEPHALOSPORIN MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 60. GERMANY CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 61. GERMANY CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 62. GERMANY CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 63. GERMANY CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 64. FRANCE CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 65. FRANCE CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 66. FRANCE CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 67. FRANCE CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 68. UK CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 69. UK CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 70. UK CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 71. UK CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 72. ITALY CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 73. ITALY CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 74. ITALY CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 75. ITALY CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 76. SPAIN CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 77. SPAIN CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 78. SPAIN CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 79. SPAIN CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 80. REST OF EUROPE CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 81. REST OF EUROPE CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 82. REST OF EUROPE CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 83. REST OF EUROPE CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 84. EUROPE CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 85. EUROPE CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 86. EUROPE CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 87. EUROPE CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 88. ASIA-PACIFIC CEPHALOSPORIN MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 89. JAPAN CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 90. JAPAN CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 91. JAPAN CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 92. JAPAN CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 93. CHINA CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 94. CHINA CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 95. CHINA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 96. CHINA CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 97. INDIA CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 98. INDIA CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 99. INDIA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 100. INDIA CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 101. AUSTRALIA CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 102. AUSTRALIA CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 103. AUSTRALIA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 104. AUSTRALIA CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 105. SOUTH KOREA CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 106. SOUTH KOREA CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 107. SOUTH KOREA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 108. SOUTH KOREA CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 109. REST OF ASIA-PACIFIC CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 110. REST OF ASIA-PACIFIC CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 111. REST OF ASIA-PACIFIC CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 112. REST OF ASIA-PACIFIC CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 113. ASIA-PACIFIC CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 114. ASIA-PACIFIC CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 115. ASIA-PACIFIC CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 116. ASIA-PACIFIC CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 117. LAMEA CEPHALOSPORIN MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 118. BRAZIL CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 119. BRAZIL CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 120. BRAZIL CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 121. BRAZIL CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 122. SOUTH AFRICA CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 123. SOUTH AFRICA CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 124. SOUTH AFRICA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 125. SOUTH AFRICA CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 126. SAUDI ARABIA CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 127. SAUDI ARABIA CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 128. SAUDI ARABIA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 129. SAUDI ARABIA CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 130. REST OF LAMEA CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 131. REST OF LAMEA CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 132. REST OF LAMEA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 133. REST OF LAMEA CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 134. LAMEA CEPHALOSPORIN MARKET, BY GENERATION, 2017-2025 ($MILLION)
TABLE 135. LAMEA CEPHALOSPORIN MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 136. LAMEA CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION, 2017-2025 ($MILLION)
TABLE 137. LAMEA CEPHALOSPORIN MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 138. ALLERGAN: COMPANY SNAPSHOT
TABLE 139. ALLERGAN: OPERATING SEGMENTS
TABLE 140. ALLERGAN: PRODUCT PORTFOLIO
TABLE 141. BMS: COMPANY SNAPSHOT
TABLE 142. BMS: PRODUCT PORTFOLIO
TABLE 143. ROCHE: COMPANY SNAPSHOT
TABLE 144. ROCHE: OPERATING SEGMENTS
TABLE 145. ROCHE: PRODUCT PORTFOLIO
TABLE 146. GSK: COMPANY SNAPSHOT
TABLE 147. GSK: OPERATING SEGMENTS
TABLE 148. GSK: PRODUCT PORTFOLIO
TABLE 149. LUPIN LIMITED: COMPANY SNAPSHOT
TABLE 150. LUPIN LIMITED: OPERATING SEGMENTS
TABLE 151. LUPIN LIMITED: PRODUCT PORTFOLIO
TABLE 152. MERCK: COMPANY SNAPSHOT
TABLE 153. MERCK: OPERATING SEGMENTS
TABLE 154. MERCK: PRODUCT PORTFOLIO
TABLE 155. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 156. NOVARTIS: OPERATING SEGMENTS
TABLE 157. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 158. PFIZER: COMPANY SNAPSHOT
TABLE 159. PFIZER: OPERATING SEGMENTS
TABLE 160. PFIZER: PRODUCT PORTFOLIO
TABLE 161. SANOFI: COMPANY SNAPSHOT
TABLE 162. SANOFI: OPERATING SEGMENTS
TABLE 163. SANOFI: PRODUCT PORTFOLIO
TABLE 164. TEVA: COMPANY SNAPSHOT
TABLE 165. TEVA: OPERATING SEGMENTS
TABLE 166. TEVA: PRODUCT PORTFOLIO
LIST OF FIGURE
LIST OF FIGURES
FIGURE 01. CEPHALOSPORIN MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. MARKET SHARE ANALYSIS, 2017
FIGURE 04. BARGAINING POWER OF BUYERS
FIGURE 05. BARGAINING POWER OF SUPPLIERS
FIGURE 06. THREAT OF SUBSTITUTION
FIGURE 07. THREAT OF NEW ENTRANT
FIGURE 08. COMPETITIVE RIVALRY
FIGURE 09. ALLERGAN: NET SALES, 2015-2017 ($MILLION)
FIGURE 10. ALLERGAN: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 11. BMS: REVENUE, 2015-2017 ($MILLION)
FIGURE 12. BMS: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 13. BMS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 14. ROCHE: NET SALES, 2015-2017 ($MILLION)
FIGURE 15. ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 16. GSK: NET SALES, 2015-2017 ($MILLION)
FIGURE 17. GSK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 18. GSK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 19. LUPIN LIMITED: NET SALES, 2016-2018 ($MILLION)
FIGURE 20. LUPIN LIMITED: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 21. MERCK: NET SALES, 2015-2017 ($MILLION)
FIGURE 22. MERCK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 23. MERCK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 24. NOVARTIS: NET SALES, 2015-2017 ($MILLION)
FIGURE 25. NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 26. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 27. PFIZER: NET SALES, 2015-2017 ($MILLION)
FIGURE 28. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 29. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 30. SANOFI: NET SALES, 2015-2017 ($MILLION)
FIGURE 31. SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 32. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 33. TEVA: NET SALES, 2015-2017 ($MILLION)
FIGURE 34. TEVA: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 35. TEVA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
